Leading the Way in the Pharmacy Sector

Leaders in Infusion are pleased to share some of its notable recent transactions from the past 12 months, highlighting the activity and breadth of the sector.

Houlihan Lokey’s Healthcare Group is excited to showcase a series of headline transactions from the past 12 months, underscoring its unmatched expertise and activity in the pharmacy sector.

If you’re ready to unlock new opportunities or explore strategic alternatives, we would be happy to connect and help you take the next step.

Michael Pisani
Managing Director
Co-Head of U.S. Healthcare

+1 214.665.8611
Email

Colby Catania
Senior Vice President

+1 212.497.7944
Email

Alex Crosby
Vice President

+1 214.665.8602
Email

Click on each transaction below to learn more.

Broad Pharmacy Supply Chain Coverage Effort

Featured Broader Pharmacy Experience

Click on each transaction below to learn more.

Tombstones included herein represent transactions closed from 2015 forward.

Upcoming Event

Our 2025 multi-industry conference will be held over three days in both New York and London. We will be spotlighting the healthcare industry on Wednesday, May 14, in New York and on Tuesday, November 18, in London. Please reach out to your Houlihan Lokey contact for more information.

About Houlihan Lokey

Houlihan Lokey, Inc. (NYSE:HLI) is a global investment bank with expertise in mergers and acquisitions, capital markets, financial restructuring, and financial and valuation advisory. Houlihan Lokey serves corporations, institutions, and governments worldwide with offices in the Americas, Europe, the Middle East, and the Asia-Pacific region. Independent advice and intellectual rigor are hallmarks of the firm’s commitment to client success across its advisory services. The firm is the No. 1 investment bank for all global M&A transactions for the past two consecutive years, the No. 1 M&A advisor for the past 10 consecutive years in the U.S., the No. 1 global restructuring advisor for the past 11 consecutive years, and the No. 1 global M&A fairness opinion advisor over the past 25 years, all based on number of transactions and according to data provided by LSEG (formerly Refinitiv).